FASN is downregulated in patients with obesity but upregulated in patients with normal weight, and the overexpression of FASN is associated with aggressive disease and poor prognosis in several cancer types, including renal cell carcinoma, colon cancer, and prostate cancer (37–40). The gene discussed is FASN; the disease is prostate cancer.